Assisted Reproductive Technology, Cardiovascular Health, Infertility, in Vitro Fertilisation, Maternal Cardiometabolic Health, Metabolic Health
Conditions
Keywords
Feasibility study, Ambulatory cardiometabolic health monitoring, Cohort
Brief summary
The main causes of death in women are conditions affecting the heart and blood vessels (cardiovascular disease, CVD). Women who have difficulties getting pregnant (infertility) may be at increased risk, but the reasons for this are not clear. Infertility itself may be linked with poorer heart and blood vessel health, or fertility treatments such as in vitro fertilisation (IVF) could increase the risk. The study aims to understand the practicalities of obtaining detailed profiling of women's pre- and post- pregnancy heart, blood vessel and metabolic health. Two groups of women in Manchester University NHS Foundation Trust, will be recruited over 2 years: 1) women planning a pregnancy, either spontaneously or with IVF treatment after infertility, 2) women who previously took part in a pregnancy health study after IVF or non-IVF conception. Participants will attend a single research appointment where they will undergo a cardiometabolic health assessment. They will have their BMI calculated, body composition measured, a measurement of how well their blood vessels work using a blood pressure cuff around the arm and/or finger and blood sampling performed. A blood pressure cuff as well as a blood sugar sensor may be fitted to be worn after the appointment. Participants will be asked to complete a questionnaire(s), with follow-up for up to 13 months. The cardiometabolic health of those who conceived with or without IVF treatment and with or without a history of infertility will be compared at both time points to investigate the possibility of links between infertility, IVF processes and CVD risk and to understand any potential barriers to recruitment of individuals at either time point to guide future studies. This information could then be used in a full-scale study, including in pregnancy, to improve care and promote lifelong health for women with infertility.
Detailed description
Objectives: Primary objective: To assess the feasibility of a pre-conception and postnatal cardiometabolic health research study in infertile and fertile individuals. Secondary objectives: * To assess clinic-measured cardiometabolic status * To measure ambulatory cardiovascular status * To measure ambulatory blood glucose concentrations * To assess the views of fertile and infertile individuals on cardiometabolic health optimisation and research in this area * To assess acceptability of cardiometabolic status measurement approaches (clinic and ambulatory measured) in fertile and infertile populations * To conduct initial exploratory investigations into whether cardiometabolic status is influenced by a history of infertility Study Design This is a prospective observational cohort study consisting of two cohorts: a pre-conception cohort and a post-pregnancy cohort made up of individuals with and without a history of infertility. All participants of either cohort will have one research visit. Individuals will be invited to attend a single face-to-face research appointment where the following will be undertaken: * • Electronic wwritten consent will be obtained by a GCP-trained member of the clinical research team and a study number allocated. * Optional consent will be obtained for access to medical records held at MFT (pertaining to any subsequent pregnancy and cardiometabolic outcomes, if in the pre-conception cohort) and to future data linkage studies related to future cardiometabolic health outcomes. * Demographic data, medical history including cardiovascular/metabolic/obstetric/gynaecological history, medication history as well as mental health history, diet, breastfeeding, exercise, education and smoking status will be recorded. * Anthropometric measurements, including height, weight, lean and fat mass (bioimpedance scale) and adiposity distribution (skin fold thickness), will be measured. BMI and waist-hip ratio will be calculated. * Non-invasive assessments of cardiovascular function will be performed, including Mobil-O-Graph (pulse wave velocity, cardiac output, blood pressure, heart rate and total vascular resistance) using a blood pressure cuff, with or without EndoPAT 2000™ (endothelial function and vascular stiffness) via finger probes before and after occlusion with a blood pressure cuff. * Blood samples (maximum 15ml of blood, equivalent to six teaspoons) for assessment of renal function, lipid levels and glucose control via HbA1C, will be collected by an appropriately trained member of the research team, analysed and clinically reported in line with routine clinical care. * An ambulatory blood pressure monitor/pulse wave analyser (Mobil-O-Graph) will be fitted (if consent provided and a machine is available) and participants requested to wear this for 24 hours following the appointment, while conducting their daily activities. Once the Mobil-O-Graph device is returned the data will be downloaded by a member of the clinical research team and analysed. * A continuous glucose monitor (CGM; FreeStyle Libre Pro IQ) will be fitted (if consent provided and a machine is available) and participants requested to wear for a minimum of 24-48 hours following the appointment, while conducting their daily activities (CGM data can be collected from a single sensor for up to 14 days). CGM data will be downloaded once the device is returned. Participants will be asked to complete a post-participation questionnaire during the visit or via an email link sent to the participant after the visit, exploring: * Views on cardiometabolic health optimisation * Acceptability of the cardiometabolic health assessment, timing, approach to investigation and overall acceptability of participation Analysis: As this is a feasibility study, analysis will be through descriptive statistics (e.g., means/medians, standard deviations/interquartile ranges for continuous variables and frequencies and percentages for categorical variables) precision estimates (i.e., width of confidence interval). We will conduct exploratory regression analyses to inform the design of adequately powered future studies. Potential impact: This study will assess the feasibility of recruiting individuals, with/without an infertility history, to a study of pre-conception and postnatal cardiometabolic status assessment. It will give initial indications of whether any difference in cardiometabolic health of infertile individuals pre-dates IVF treatment and/or persists or resolves in the short-term post-delivery. It will be the first to use ambulatory measures of cardiometabolic health (such as wearable blood pressure and glucose monitors), which may have increased sensitivity to detect subtle signs of (differences in) cardiometabolic (dys)function during normal activity, compared with single time point measures during clinical visits. Ultimately, a better understanding of cardiometabolic dysfunction in infertile individuals may enable pre- or post- conception intervention (dietary, exercise and potentially pharmacological treatment) to optimise health before, during and after pregnancy in a life course approach to women's health (with anticipated positive impacts on the health of any resulting infant(s)).
Interventions
None listed
Sponsors
University of Manchester
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
FEMALE
Age
16 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* In pre-conception cohort: * Aged between 16 and 45 * Able to provide informed consent * Either: 1) Those with a history of infertility (failure to conceive after at least 1 year of unprotected intercourse/3-6 cycles of Intra-Uterine Insemination (IUI) or diagnosed cause of infertility) and accepted for IVF at The Department of Reproductive Medicine, MFT or, 2) attending for a pre-conception appointment at MFT * Nulliparous (no previous pregnancies beyond 20 weeks) * No pre-existing heart disease, hypertensive disease, vascular disease or diabetes * In post-pregnancy cohort * Aged between 16 and 45 * Able to provide informed consent * Participant of START clinic study (achieved pregnancy via a) IVF with or without ICSI treatment, b) spontaneous conception without medical intervention within 12 months, or c) spontaneous conception following ovulation induction for delay in spontaneous conception \>12 months or confirmed anovulation)
Exclusion criteria
\- In all participants: * Prisoners * Born male at birth * Language barrier not overcome by telephone or video interpretation services * Pregnant at time of study visit Pre-conception participants only: • Accepted for IVF for non-infertility reasons i.e. egg donation, egg collection, egg banking, gestational surrogacy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of recruitment | Through study duration, approximately 23 months | Number of recruits |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Recruitment acceptance | Through study duration, approximately 23 months | Proportion of eligible individuals accepting recruitment |
| Time taken to achieve the proposed sample size | Recruitment period, approximately 23 months | Time taken to achieve the proposed sample size |
| Acceptance of the investigative methods | Through study duration, approximately 23 months | Proportion of individuals accepting each type of investigation |
| Duration of ambulatory monitoring | Up to 14 days post-study visit | Duration of ambulatory monitoring completed per participant |
| Consent to data linkage | Through study duration, approximately 23 months | Proportion of individuals consenting to data linkage |
| Participant questionnaire asking about importance of cardiometabolic health optimisation and research in this area | Through study duration, approximately 23 months | Participant-reported importance of cardiometabolic health optimisation and research in this area via electronic questionnaire. Participants will be asked to rank on a Likert scale (strongly disagree to strongly agree) whether they would consider taking part in a similar study in the future, whether they would recommend the study to a friend, whether the research topic is important to them and would they improve their health if they knew their cardiometabolic health was below average. |
| Participant questionnaire asking about acceptability of participation and of measurement techniques in the study | Through study duration, approximately 23 months | Participant-reported acceptability of participation and of individual measurements. Participants will be asked to rank on a Likert scale (strongly disagree to strongly agree) how they felt about the acceptability of measurements performed in clinic as well as ambulatory measurements (if applicable). |
| Variability between cohort differences in cardiometabolic health markers | Following analysis of data, an average of 3 years from study start | Preliminary variability between cohort differences in cardiometabolic health markers, to identify potential useful investigations for future studies. Example health markers include adiposity differences (BMI, waist-hip ratio), non-invasive assessments of cardiovascular function (in-clinic and ambulatory Mobil-O-Graph results), serum renal function, lipid levels and HbA1C and ambulatory CGM measurements. |
| Proportion of pre-conception participants who conceive within a year of the study visit | A year after participant's study visit | Proportion of pre-conception participants who conceive within a year of the study visit |
Contacts
CONTACTLucy Higgins, MBChB PhD MRCOG
CONTACTSarah Willetts, BMedSci MBChB
Outcome results
None listed